Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Recruiting

Phase 1

Experimental DrugsDose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT06975787

Conditions

Lupus Nephritis (LN)

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Vonsetamig

Odronextamab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-30. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-03-25.